Clinical Trials in Nashville

Showing 5481-5500 of 20,298 trials

Metabolic Effects of Angiotensin-(1-7)

NCT02646475

The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.

ObesityInsulin ResistanceHypertension+1 more

Vanderbilt University26 participantsStarted Feb 2016

Nashville, Tennessee, United States

COMPLETEDPhase 2< 1 mile

A Study of SEA-CD40 Given With Other Drugs in Cancers

NCT04993677

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

MelanomaCarcinoma, Non-Small- Cell Lung

Seagen Inc.77 participantsStarted Oct 2021

Springdale, Arkansas, United States • Los Angeles, California, United States • San Francisco, California, United States +26 more locations

Metabolic Effects of Angiotensin-(1-7)

A Study of SEA-CD40 Given With Other Drugs in Cancers

Find Trials by Condition in Nashville

Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Adalimumab in JIA-associated Uveitis Stopping Trial

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Impairments That Affect Correct Inhaler Use in COPD

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Evaluating the Safety and Effectiveness of the InnAVasc Graft for Dialysis Access in Patients With Kidney Failure

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

SHARPEN - Parkinson's Disease Dementia

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Trauma Informed Guilt Reduction Therapy

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma